Mar 30,2020

Nemaura to launch new digital brand proBEAT™ in the USA, Targeting a Market of over 100 Million potential users with its Prescription-Free Consumer Wellness Glucose Monitoring Device and Digital Healthcare Subscription Service

Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and digital solutions for the medical and consumer markets, announced it is planning to launch a digital healthcare subscription service in the USA under the brand name proBEAT™.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 01,2020

Nemaura Plans To Launch Body-Worn Continuous Temperature Monitor (CTM) to Track Fever Caused by Viral Infections such as COVID-19

Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), announced plans for a new product line by seeking to immediately repurpose sugarBEAT® as a CTM since its inbuilt temperature sensor is capable of continuously tracking body temperature through the skin.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 08,2020

ABBOTT'S FREESTYLE® LIBRE 14 DAY SYSTEM NOW AVAILABLE IN U.S. FOR HOSPITALIZED PATIENTS WITH DIABETES DURING COVID-19 PANDEMIC

Abbott (NYSE: ABT) announced today that the FreeStyle Libre 14 day system, the world's leading3 continuous glucose monitoring (CGM) technology, can now be used in the hospital setting2 during the COVID-19 pandemic, according to the U.S. Food and Drug Administration (FDA).

PRODUCT

#cgm

#rpm

View Analyst & Ambassador Comments
Go to original news
Apr 08,2020

Dexcom Continuous Glucose Monitoring Systems to be Temporarily Offered to Hospitals During COVID-19 Emergency

Dexcom announced today that due to the public health crisis of COVID-19 and the need to preserve personal protective equipment and reduce the frequency of hospital staff exposure to the coronavirus, the company is making its Dexcom G6 CGM System temporarily available for remote patient monitoring in the hospital setting. This decision was made based on feedback received from the U.S. Food and Drug Administration (FDA).

PRODUCT

#rpm

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 21,2020

Nemaura Secures $5 Million Loan to Accelerate Commercial Strategy

Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), today announced it has secured a 24-month, $5 million non-convertible loan.

FUNDING POST-IPO EQUITY

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 27,2020

Dexcom to Launch Patient Assistance Program for Current U.S. Customers Impacted by COVID-19 Pandemic

Dexcom announced today a new patient assistance program to aid current U.S. customers who have lost insurance due to the COVID-19 pandemic.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
May 05,2020

Nemaura Medical Announces Interview with CEO to Air on May 11

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), today announced an interview with its CEO, Dr. Faz Chowdhury, will be available for viewing beginning Monday, May 11, 2020, on RedChip Companies YouTube channel.

#cgm

View Analyst & Ambassador Comments
Go to original news
May 22,2020

Medtronic Guardian™ Connect Continuous Glucose Monitoring (CGM) System for Diabetes Now Compatible with Android Devices

Medtronic (NYSE:MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) approval for the Android™ version of its Guardian™ Connect continuous glucose monitoring (CGM) system.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 25,2020

Continuous blood glucose monitoring: the Menarini Diagnostics digital “patch” now available!

Measuring blood sugar several times a day for people with diabetes, will no longer be necessary. Menarini Diagnostics has launched GlucoMen® Day CGM, an innovative digital patch, wearable fourteen days in a row, which monitors blood glucose and shows results directly on the smartphone.

PRODUCT

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 01,2020

Flash glucose monitoring helps achieve better glycemic control than conventional self-monitoring of blood glucose in non-insulin-treated type 2 diabetes: a randomized controlled trial

The present study aimed to evaluate the effects of flash glucose monitoring (FGM) and conventional self-monitoring of blood glucose (SMBG) on glycemic control in patients with non-insulin-treated type 2 diabetes.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM